Untersuchungszentrum Dermatologie, Allergologie und Asthma, Berlin, Germany Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT00973453
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

UZDAA, Untersuchungszentrum Dermatologie, Allergologie und Asthma, Berlin, Germany

Active Ingredients

Drugs in Phase 2 Trials (1)

house dust mite allergen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1